Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

777 > 777 final ADHD > Flashcards

777 final ADHD Flashcards

1
Q

Attention Deficit Hyperactivity Disorder

A

Persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development
Hyperactive-impulsive type
Inattentive type
Combined type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ADHD

A

Neurodevelopmental disorder
Preschooler, children, adolescents, and adults
Characterized by a pattern of diminished sustained attention and increased impulsivity
Clear evidence to support a biological basis for ADHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

DSM-5 Changes

A

ADHD symptoms present by age 12 rather than 7
Inattentive and hyperactive subtypes replaced by 3 specifiers
1. Combined presentation
2.Predominantly inattentive presentation
2. Predominantly hyperactive/impulsive presentation
Comorbid ADHD and ASD
Fewer criteria for adolescents 17 and older and adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Epidemiology

A

5% of children, 2.5% of adults
Most frequent psychiatric disorder in childhood
Most cultures
More frequent in males by 2:1 ratio in children and 1.6:1 in adults
Females more likely to have inattentive features

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diagnostic Features

A

Persistent pattern of inattention and/or hyperactivity-impulsivity
Interferes with functioning or development
Begins in childhood
Manifestations of the disorder present in more than one setting
Symptoms vary depending on setting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Associated Features

A

Mild delays in language motor or social development
Low frustration tolerance
Irritability
Mood lability
Impaired academic or work performance
Increased risk of suicide esp when co-morbid with mood, substance or conduct disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Development and Course

A

Toddler and preschoolers: excessive motor activity
School age: inattention more prominent
Hyperactivity less obvious in adolescence and adulthood, restlessness, impatience, poor planning feeling like one is driven by a motor, impulsivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Attention Difficulties

A 
Inattention
Lacking persistence
Difficulty sustaining attention
Disorganization
Hyperactivity
Excessive motor activity
Excessive restlessness, fidgeting, tapping talkativeness
Adults wearing others out with activity
Impulsivity
Hasty actions and decisions with high harm potential and without forethought and consideration for long-term consequences 
Desire for immediate reward
Inability to delay gratification
Social intrusiveness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sustained Attention Deficiencies in ADHD

A

Executive dysfunction
Inability to sustain attention and solve problems
Hypothetically linked to inefficient information processing in the dorsal lateral prefrontal cortex (DLPFC)
DLPFC activated by the n-back test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Selective Attention Deficiencies in ADHD

A

Difficulty with selective attention
Inability to focus
Hypothetically linked to the dorsal anterior dorsal anterior cingulate cortex (dACC)
dACC can be activated by the Stroop test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Risk Factors

A 
Environmental
Genetic 
Neurochemical
Neurophysiological
Neuroanatomical
Psychosocial
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Environmental Factors

A 
Very low birth weight (< 1500 grams 3.3 pounds) 2-3X the risk
Maternal smoking
ETOH exposure in utero
Lead exposure
Dietary: food coloring, additives
Disorganized chaotic households
Poverty
Head trauma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Genetic

A

Substantial heritability
Increased concordance in monozygotic twins
2-8 times the risk if a sibling or parent has ADHD
Association of dopamine transporter gene (DAT1) with ADHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Neurotransmitters and ADHD

A

DA and NE dysregulation prevents normal tuning of pyramidal neurons in the PFC

DA and NE imbalances hypothetically cause inefficient information processing in prefrontal circuits

Hypothetically associated with excessive signaling in prefrontal DA and NE pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Neurobiology of Attentional Disorders

A

ADHD as a disorder of the prefrontal cortex
Trio of symptoms
Inattention
Difficulties with sustained and selective attention
Hyperactivity
Modulated by a cortico-striato-thalamo-cortical loop from PFC to the putamen to the thalamus and back to the PFC
Impulsivity
Hypothetically linked to the orbitofrontal cortex (OFC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Neurodevelopment and ADHD

A

Classic: onset by age 7
Formation of synapses and the selection of synapses for removal in the PFC occur in childhood
May be a disruption causing prefrontal abnormalities
Some children compensate and “grow out of the ADHD”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Neurodevelopment and ADHD (continued)

A

Hypotheses
Abnormal synapse formation
Abnormal synaptic neurotransmission
Genes involved are linked to DA neurotransmission
Genes under investigation are linked to a2A adrenergic receptor, serotonin receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Synaptogenesis and Development

A

Age 1: working memory emerges
3-4 years: minimal capability to sustain attention
6-7 years: sustained attention and planning
Synaptic pruning taking place

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Comorbidity

A 
Oppositional defiant disorder
Conduct disorder
Learning disorders
Disruptive mood dysregulation disorder
Anxiety
Depression 
Substance use
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ADHD Symptoms Across the Lifespan

A 
Preschool
Behavioral disturbances
School age
Behavioral disturbances
Academic problems
Difficulty with social interactions
Self-esteem issues
Adolescence
Academic problems
Difficulty with social interactions
Self-esteem issues
Legal issues
Smoking and injury
College age
Academic failure
Occupational difficulties
Self esteem issues
Substance abuse
Injury/accidents
Adulthood
Occupational failure
Self-esteem issues
Relationship problems
Injury/accidents
Substance abuse
21
Q

Consequences of ADHD

A

Decreased school/occupational performance and academic/occupational attainment
Increased social and peer rejection
Children more likely to develop conduct disorders
Increased substance use disorders
Increased accidental injuries, traffic violations
Increased interpersonal conflict

22
Q

Diagnosis and Treatment of ADHD Across the Lifespan

A

Rates of diagnosis differ
Due to differences in referral patterns
Children: teachers, parents, pediatricians, psychologists
Adults: self-referred and often have a comorbidity
Treatment differences
2/3 of all stimulant use for ADHD is inpatients under 18
2/3 of all atomoxetine use is in adults

23
Q

ADHD Assessment

A 
Psychiatric evaluation/clinical interview
Context in which symptoms occur
Age of onset
Educational evaluation
Family evaluation
Rating Scales:
Vanderbilt ADHD Parent and Teacher
Connors Rating Scales-Revised (CRS-R)
Brown Attention Deficit Disorder Scales (BADDS)
Adult ADHD Self-Report Scale (ASRS-1)
TOVA
24
Q

American Academy of Pediatrics (AAP) Guidelines for Diagnosis and Treatment

A

Guidelines address ADHD in ages 4-18 (expanded age range)
Primary care clinicians evaluate any child presenting with behavioral or academic problems as well as hyperactivity, inattention or impulsivity
Includes pre-schoolers
Inclusion of adolescents acknowledges the children that do not “outgrow” ADHD and those dx for the 1st time in their second decade
Diagnosis confirmed by info from parents, teachers and others involved in child’s care
Other causes should be ruled out
Stressful life events and medications can also mimic ADHD symptoms

Assess for co-existing conditions
Chronic condition
Evidence-based parent and/or teacher-administered behavior therapy should be first line
Methylphenidate for those that do not respond to behavioral therapy

25
Q

ADHD: Psychotherapy

A

Psychoeducation
Focused behavioral therapy
Set clear limits with clear expectations
Establish/maintain predictable, calm environment with decreased stimuli
Establish eye contact before giving instructions
Ask to repeat what was heard
Limit distractions for homework and encourage one assignment at a time
Develop effective coping skills
Family therapy
School interventions and accomadations

26
Q

Treatment Principles for Comorbidities in ADHD

A

What disorder is prioritized?
ADHD treatment often seen as secondary
Keep an index of suspicion for ADHD in the presence of mood, anxiety, substance abuse
ADHD treatments as augmenting agents to first line tx of mood, anxiety and substance
Treat nicotine dependence

27
Q

Principles of Stimulant Treatment

A

Increase release of DA and NE
Stimulants and by some noradrenergic agents
Adults with anxiety, depression, substance abuse
Augment antidepressant or anxiolytic therapies
NET inhibitor (NRI’S)
a2A –adrenergic agonist (Guanfacine, Clonidine)

28
Q

Methylphenidate (D)

A

Mechanism of action
Blocks reuptake of DA and NE
Enhances DA and NE in the DLPFC: increased attention, concentration, executive function and wakefulness
Enhances DA in basal ganglia: may improve hyperactivity
Enhances DA and NE in medial prefrontal cortex: may improve depression, fatigue sleepiness

Side effects
Insomnia, headache, exacerbation of tics, nervousness, irritability, anorexia, weight loss, palpitations, increased B/P
High abuse potential
Dosing
IR: 2.5 – 10mg BID
ER: 10 – 20mg/day

Drug interactions
May inhibit metabolism of SSRI’s, anticonvulsants, tricyclic antidepressants, coumarin
Serious adverse effects may occur if combined with clonidine
Not advised for use with MAOI’s
Precaution
Hypertension, hyperthyroidism, drug abuse

29
Q

Methylphenidate (D) Special Populations

A 
Elderly: lower doses
Children: not approved under 6
Monitor weight and height
Pregnancy: Category C
Breast feeding: not recommended
30
Q

Methylphenidate (D, L)

A

IR formulations: 2-4 hour duration of action
Ritalin, Methylin, generic methylphenidate
Chewable tablets
Oral solutions
Dosing initial 5mg QAM 5mg at lunch increase 5-10mg each week max dose 60mg
SR formulations
Older ER: Ritalin SR, Methylin SR, Metadate ER: duration of action 4-6 hours, dosing 20-30mg/day in divided doses
Newer ER: Concerta up to 12 hours initial dosing 18mg to 72mg, Ritalin, LA Metadate CD up to 8 hours 20-60mg/day
Transdermal formulation
initial dosing 10mg/9 hours increase by 5mg max dose 30mg
Apply patch 2 hours before needed effect, wear for 9 hours
May be possible to dose only during the school week
Drug holidays
Avoid dosing late in the day

31
Q

Amphetamine

A

Blocks transporters for DA and NE
Competitive inhibitor and pseudosubstrate for NET and DAT
d and l-isomer
d- isomer more potent for DAT binding
d and l-isomers equally potent for NET binding

32
Q

SR Stimulants

A

SR stimulants optimize rate, amount, and length of time that a stimulant occupies NET and DAT
Goal: occupy enough of the NET in the PFC
At a slow enough pace and long enough duration to enhance tonic NE signaling via a2A receptors
Increase tonic DA signaling via D1 receptors
Occupy little enough of the DAT in nucleus accumbens not to increase phasic signaling

33
Q

Amphetamine (D)

A 
Dexedrine, Dexedrine Spanules, Dextro Stat
Mechanism of action
Increases NE and DA by blocking reuptake and facilitating release
Enhances DA and NE in DLPFC
Enhances DA in basal ganglia
Enhances DA and NE in medial PFC
Pharmacokinetics half-life 10-12 hours
High abuse potential
May be able to give drug holidays

Monitor B/P
Children monitor height and weight
Drug Interactions
MAOI’s slow absorption of amphetamines
Can raise corticosteroid levels
May antagonize hypotensive effects of veratrum alkaloids and other antihypertensives
May increase analgesic effects of meperidine

34
Q

Amphetamine (D) Special Populations

A 
Elderly: caution, lower dose
Children 
Not approved for under 3
Acute effects on growth hormone
Ages 3-5 (ADHD) initial 2.5mg
Pregnancy
Category C
Breast-feeding: not recommended
35
Q

Amphetamine (D,L)

A

Adderall and Adderall XR
Pharmacokinetics
Mixture of d-amphetamine and l-amphetamine salts in a ratio of 3:1
Adult ½ life of d-amphetamine = 10 hours and l-amphetamine = 13 hours
Children ½ life of d-amphetamine = 9 hours and l-amphetamine = 11 hours

36
Q

Lisdexamfetamine

A

Mechanism of Action
Prodrug of dextroamphetamine
Increases NE and DA actions by blocking reuptake and facilitating their release
Enhances DA and NE in DLPFC
Enhances DA in basal ganglia
Enhances DA and NE in medial PFC
Pharmacokinetics: duration of action 10-12 hours
Dosing
Initial 30mg QAM increase 10-20mg/week up to 70mg

37
Q

Lisdexamfetamine Special Populations

A 
Elderly lower doses
Children and Adolescents
Safety and efficacy not established under 6
Acute effects on growth hormone
Pregnancy
Category C
Breast Feeding
Not recommended
38
Q

Noradrenergic Treatments

A

Atmoxetine
Buproprion
Desimprimine
Nortriptylene

39
Q

Atomoxetine

A

Mechanism of Action
Boosts NE/NA and my increase DA in PFC
Block NE pumps
Increases noradrenergic neurotransmission
Side Effects
Sedation, fatigue, increased heart rate, increased B/P, sexual dysfunction
Dosing
Children: over 70kg or less initial 0.5mg/kg/day after 7 days increase to 1.2mg/kg/day up to 100mg/day
Adults: 40mg/day after 7 days increase to 80mg/day up to 100mg/day

Pharmacokinetics
Metabolized by CYP450 2D6
½ life 5 hours
Drug Interactions
Plasma concentrations of Atomoxetine may be increased by drugs that inhibit CYP 450 2D6 (paroxetine, fluoxetine)
Do not use with MAOI’s (21 days after discontinuation)

40
Q

Atomoxetine and Special Populations

A 
Elderly
Lower dose
Reduction of suicidality with antidepressants in adults over 65
Children and Adolescents
Approved to treat ADHD in 6 and over
Do not use with serious cardiac problems
Monitor for suicidal ideation
Pregnancy	
Category C
Breast-Feeding
Not recommended
41
Q

Alpha-2A-Adrenergic Agonists

A

Alpha 2-A receptors primary mediators of NE in PFC
2 direct acting agonists for a2 receptors
Guanfacine
Guanfacine ER
Clonidine

42
Q

Treatment with Guanfacine and Clonidine

A

Clonidine more side effects, less selective agonist on a2 receptors
Guanfacine 15-20X more selective for a2 receptors, 10X weaker than Clonidine at inducing sedation and lowering B/P
25X more potent in enhancing PFC function
Can be used adjunctively with stimulants to treat patients with oppositional symptoms
ADHD caused by low NE in PFC without additional impairments in DA neurotransmission good candidates for Guanfacine ER monotherapy (no way to ID these patients other than a trial of meds)

43
Q

Guanfacine

A

More selective for a2A receptors
Guanfacine ER once a day dosing
Guanfacine ER approved for ADHD ages 6-17
Treatment of Tic disorders

Mechanisms of Action
Central action on postsynaptic alpha 2A receptors in PFC
10-15X more selective for alpha 2A than alpha 2B or 2C
Side Effects
Hypotension B/P lowered 30-60 minutes after first dose; greatest reduction after 2-4 hours
Sedation
Rebound HTN with abrupt termination
Dosing: IR and ER
IR: 1mg/HS after 3-4 weeks increase to 2mg
ER: 1mg/HS; increase 1mg/week; max dose 4mg/day

44
Q

Guanfacine (continued)

A

Pharmacokinetics
Metabolized by CYP450 3A4
Drug Interactions
CYP450 3A inhibitors (nefazodone, fluoxetine, fluvoxamine and ketoconazole) may decrease clearance thereby increasing guanfacine levels
CYP450 3A inducers may increase guanfacine clearance
Do not administer ER with high fat meals

45
Q

Guanfacine and Special Populations

A 
Elderly
Elimination ½ life may be longer
More sensitive to sedative effects
Children and Adolescents
Safety and efficacy not established in children under 6
Pregnancy
Category C
Breast-Feeding
No recommended
46
Q

Clonidine

A

Mechanisms of Action
Nonselective agonist at a2 receptors with actions on a2A, a2B and a2C receptors
Interacts at imidazoline receptors which may be the cause of sedating and hypotensive actions
Side Effects
Sedation
Hypotension B/P lowered 30-60 minutes after first dose; greatest reduction after 2-4 hours
Dosing
Initial 0.1mg/bedtime, can increase by 0.1mg/week in divided doses with increased dose at HS max dose 0.4mg/day
Taper

47
Q

Clonidine (continued)

A

Pharmacokinetics
½ life 12-16 hours
Metabolized by the liver
Excreted renally
Drug Interactions
Increased CNS depressive and sedative effects when combined with other CNS depressants
Severe discontinuation rxn when combined with beta blockers

48
Q

Clonidine and Special Populations

A

Elderly
Lower doses
More sensitive to sedative effects
Caution with beta blockers
Children and Adolescents
Safety and efficacy not established under 6
May be more sensitive to hypertensive effects of withdrawal
More likely to experience CNS depression with OD, may have signs of toxicity at 0.1mg
Pregnancy
Category C
Breast-Feeding
No adverse effects have been reported in nursing infants

49
Q

Future Treatments

A

H3 antagonists
Boosting acetylcholine function in PFC
a-nicotinic receptor agonists
a4B2-nicotinic receptor

777 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions